E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and Regeneration

Graphical Abstract

Highlights

- The PIDDosome controls hepatocyte ploidy during postnatal development & regeneration
- The PIDDosome defines the speed of liver regeneration posthepatectomy
- Aneuploidy in the liver correlates with basal ploidy state but is not limited by CASP2
- E2F family members regulate expression of CASP2 and PIDD1 for liver ploidy control

Authors
Valentina C. Sladky, Katja Knapp, Claudia Soratroi, ..., Floris Foijer, Alain de Bruin, Andreas Villunger

Correspondence
andreas.villunger@i-med.ac.at

In Brief
Sladky et al. report a key role for the PIDDosome in regulating p53 activation to limit hepatocyte polyploidy during juvenile liver growth and regeneration. Expression of essential PIDDosome components is controlled by a E2F-family regulated circuitry. The study defines the PIDDosome as a putative target to enhance liver regeneration.
E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and Regeneration


1Division of Developmental Immunology, Biocenter, Medical University of Innsbruck, 6020 Innsbruck, Austria
2Department of Pathobiology, Faculty of Veterinary Medicine, Utrecht University, 3584 CL Utrecht, the Netherlands
3European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, 9713 AV Groningen, the Netherlands
4Department of Surgery, Medical University of Vienna, General Hospital, 1090 Vienna, Austria
5Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, 1090 Vienna, Austria
6Medical University of Graz, Clinical Institute of Medical and Chemical Laboratory Diagnostics, 8010 Graz, Austria
7Armenise-Harvard Laboratory of Cell Division, Department of Cellular, Computational and Integrative Biology - CIBIO, University of Trento, 38123 Povo, Italy
8Department of Pediatrics, University Medical Center Groningen, University of Groningen, 9713 AV Groningen, the Netherlands
9Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, 1090 Vienna, Austria
10Department of Pathobiology, Faculty of Veterinary Medicine, Utrecht University, 3584 CL Utrecht, the Netherlands
11CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria
12Lead Contact

*Correspondence: andreas.villunger@i-med.ac.at

SUMMARY

E2F transcription factors control the cytokinesis machinery and thereby ploidy in hepatocytes. If or how these proteins limit proliferation of polyploid cells with extra centrosomes remains unknown. Here, we show that the PIDDosome, a signaling platform essential for caspase-2-activation, limits hepatocyte ploidy and is instructed by the E2F network to control p53 in the developing as well as regenerating liver. Casp2 and Pidd1 act as direct transcriptional targets of E2F1 and its antagonists, E2F7 and E2F8, that together co-regulate PIDDosome expression during juvenile liver growth and regeneration. Of note, whereas hepatocyte aneuploidy correlates with the basal ploidy state, the degree of aneuploidy itself is not limited by PIDDosome-dependent p53 activation. Finally, we provide evidence that the same signaling network is engaged to control ploidy in the human liver after resection. Our study defines the PIDDosome as a primary target to manipulate hepatocyte ploidy and proliferation rates in the regenerating liver.

INTRODUCTION

Polyploidization, the balanced amplification of the whole genome, is commonly observed in plants, insects, and fungi, as well as in some vertebrates, including frogs and fish (Gjelsvik et al., 2019; Otto, 2007). In contrast, mammalian cells are mainly diploid, and polyploidy is noted as a potential danger facilitating chromosomal instability (CIN) and thereby transformation (Holland and Cleveland, 2009). Thus, polyploidy is limited to certain tissues and cell types where it is considered beneficial for the execution of organ-specific functions, such as protection of the urothelium, muscle cell contraction, platelet shedding or, counterintuitively, the protection from liver cancer (Abmayr and Pavlath, 2012; Pang et al., 2005; Wang et al., 2018; Zhang et al., 2018a). Remarkably, the generation of polyploid cells during organogenesis frequently involves incomplete cytokinesis (Lans and Medema, 2019; Pandit et al., 2013). In the rodent liver, physiological polyploidization starts at the time of weaning when diploid hepatocytes fail to complete cytokinesis and generate binucleated, tetraploid progeny. Following this first wave of polyploidization, hepatocytes either divide normally to generate mononucleated tetraploid cells or fail cytokinesis again to become octaploid (Celton-Morizur et al., 2009; Margall-Ducos et al., 2007). Yet, polyploid cell divisions with clustered centrosomes or multipolar mitoses are prone to segregation errors generating CIN and aneuploid progeny, which is often detrimental even for cancer cells (Holland and Cleveland, 2009; Tang and Amon, 2013). In the liver, however, this has not been formally demonstrated in vivo but aneuploidy was proposed to be beneficial by providing genetic diversity posing an advantage in adaption to various stressors or injury and is also frequently observed in hepatocellular carcinoma (Cancer Genome Atlas Research Network, 2017; Duncan et al., 2012a). This suggests a certain trade-off between fast adaptation to hepatotoxic stress and increased cancer risk. The actual degree of aneuploidy in the liver, however, remains a matter of debate (Duncan et al., 2010, 2012b; Knouse et al., 2014, 2018).
Hepatocyte polyploidization is a well-organized process best studied in mice where its onset during weaning is controlled by increases in insulin levels (Celton-Morizur et al., 2009; Margall-Ducos et al., 2007). Moreover, hepatocyte ploidy is regulated by members of the E2F family of transcription factors, which control expression of key proteins required for cell cycle progression and cytokinesis (Chen et al., 2012; Conner et al., 2003; Pandit et al., 2012). While the transcriptional activator E2F1 promotes normal cell division, the atypical, partially redundant E2F family members, E2F7 and E2F8, repress transcription of several cytokinesis effectors such as ECT2, MKLP1, or RACGAP and thereby facilitate cytokinesis failure. Consistently, overexpression of E2F1 or liver-specific co-deletion of E2F7 and E2F8 prevents weaning-induced polyploidization. As a consequence, hepatocytes in these mice are largely diploid (Chen et al., 2012; Conner et al., 2003; Pandit et al., 2012). In contrast, ablation of E2F1 results in an even further increase of hepatocyte ploidy (Chen et al., 2012; Pandit et al., 2012). Whereas the physiological relevance of increased ploidy for liver function remains unclear, recent evidence suggests that it protects from tumorigenesis, presumably by providing a reservoir of tumor suppressors in hepatocytes (Kent et al., 2016; Zhang et al., 2018a, 2018b). The exact molecular basis limiting natural polyploidization in the adult or regenerating liver, however, remains to be defined. A well-established player in this process is p53, shown to limit liver ploidy during development and regeneration (Kurinna et al., 2013). How p53 becomes activated in hepatocytes to restrict polyploid in organogenesis or tissue repair remains unclear.

Caspase-2 is a member of the caspase family of endopeptidases, which are best known for their functions in cell death and inflammation (Mcllwain et al., 2013). Caspase-2 contains a caspase activation and recruitment domain (CARD) required for activation (Boucher-Hayes and Green, 2012; Kumar, 2009). As such, caspase-2 is structurally similar to the initiator caspases-1, -4, -5, and -9 that become activated in inflammasomes or the apoptosome, respectively (Mcllwain et al., 2013). The protein complex needed for caspase-2 activation was dubbed the PIDDosome and is formed by PIDD1 and RAIDD/CRADD that protein complex needed for caspase-2 activation was dubbed the PIDDosome and is formed by PIDD1 and RAIDD/CRADD that

RESULTS

The PIDDosome-p53 Axis Regulates Hepatic Ploidy during Postnatal Liver Development

To analyze the role of the PIDDosome in liver ploidy, we used flow cytometry to determine the DNA content of hepatocytes isolated from adult mice. We found that hepatocytes lacking any one of the three PIDDosome components showed increased ploidy, comparable to those isolated from livers of p53−/− or p21−/− mice (Figure 1A), confirming previous results (Fava et al., 2017; Kurinna et al., 2013; Sheahan et al., 2004). All mouse mutants tested showed an on average 30% higher mean DNA content, depicted as weighted mean ploidy (Figure 1A).

Next, we investigated the timing of PIDDosome activation during developmental hepatocyte polyploidization. In order to synchronize this process, mice were weaned at the age of 20 days and DNA content was analyzed either before (day 20) or after separation from their mothers (days 22, 25, and 28). Regardless of the genotype tested, the majority of hepatocytes were found to be diploid before (day 20) and shortly after weaning (day 22). Five days post-weaning, however, most hepatocytes had undergone at least one round of cell division and incomplete cytokinesis (Figure 1B). Importantly, in WT hepatocytes, this coincided with the loss of the pro-form of caspase-2, indicating its autoproteolytic activation (Butt et al., 1998), as well as with p53 induction (Figures 1C and S1A). In contrast, caspase-2-deficient hepatocytes failed to activate p53 and showed a significant increase in mean ploidy over time, most pronounced on day 28 (Figures 1B and S1A). Of note, at this point of analysis, p53 returned to basal levels (Figure S1A). p53 activation after weaning was strictly PIDDosome-dependent (Figure 1C). Consistently, PIDDosome deficiency results in enhanced polyploidization mirroring the one noted in p53−/− or p21−/− mice (Figures 1A and 1C). Together, these data show that p53 is engaged by the PIDDosome to limit excessive hepatocyte polyploidization.

Surprisingly, hepatic ploidy continuously increased with age in WT and PIDDosome-deficient mice alike (Figure 1D), suggesting only transient action of the PIDDosome at the time of weaning. Thus, we analyzed the levels of the PIDDosome mRNA and/or protein, during postnatal liver development and found that indeed Casp2, Pidd1, and Raidd transcript levels declined with increasing ploidy and age (Figure 1F). RAIDD protein levels, however, remained stable over time, whereas the pro-form of caspase-2 did not re-accumulate following...
Figure 1. The PIDDosome-p53 Axis Regulates Hepatic Ploidy during Postnatal Liver Development

(A) Representative histograms and weighted mean ploidy quantification of hepatocytes isolated from 12- to 14-week-old male mice of the indicated genotypes. The formula used can be found in the statistics section. Hepatocytes were fixed and stained with propidium iodide to analyze DNA content by flow cytometry (n = 3–8 per time point; detailed mouse numbers are shown in Table S7).

(B) Analysis of CASP2, RAIDD, and p53 protein in hepatocytes isolated from mice of the indicated genotypes, before (20 days), and 5 days after weaning (25 days). (C) Representative histograms of WT and PIDDosome-deficient hepatocytes at the age of 15 months and weighted mean ploidy analyzed over time. p53−/− and p21−/− hepatocytes were analyzed at 20 days, 25 days, 2 months, and 4 months (n = 3–8).

(D) Time-course analysis of caspase-2 and RAIDD protein levels in WT hepatocytes.

(F) PIDDosome mRNA levels were assessed in isolated hepatocytes by qRT-PCR before and at indicated time points after weaning. Data were analyzed with respect to the weighted mean ploidy. Transcript levels negatively correlate with increasing ploidy as reflected by Spearman’s correlation coefficient (linear regression: Casp2 $r^2 = 0.3158$, p = 0.0035; Raidd $r^2 = 0.1766$, p = 0.0458; Pidd1 $r^2 = 0.2735$, p = 0.0216). Mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
PIDDosome-dependent autoproteolytic activation at the time of weaning (Figure 1E). Mouse PIDD1 protein expression was not detectable by western blotting with commercially available antibodies in hepatocyte extracts. The transcriptional downregulation of Casp2 and Pidd1 coincides with further polyploidization (Figures 1D and 1E), indicating that developmental inactivation of the PIDDosome is required to facilitate homeo-

static proliferation of polyploid hepatocytes in the presence of extra centrosomes. Remarkably, increased liver ploidy in PID-

Dosome mutant mice had no or only marginal effects on liver function, based on the analysis of ALT, AST, bilirubin, urea, cholesterol, and triglycerides in sera of 4- or 15-month-old mice (Figure S1B).

The PIDDosome Restricts Polyploidization during Liver Regeneration

Hepatocytes in the regenerating liver can abort cytokinesis and p53 controls the extent of ploidy increase in this setting (Kurinna et al., 2013; Sigal et al., 1999). Despite the noted downregulation of Casp2 and Pidd1 after weaning, we wondered if the PIDDosome is still involved in ploidy control in the adult liver or if p53 is activated by alternative routes during regeneration. In order to test this, we performed 68% partial hepatectomy (PH) on 12–14-week-old mice of different genotypes and analyzed recovery of liver mass as well as hepato-

cyte ploidy. In line with previous reports, polyploidy increased during regeneration and peaked between 48 and 72 h post-

resection in a p53-dependent manner (Kurinna et al., 2013; Sigal et al., 1999; Wilkinson et al., 2018) (Figures 2A–2C and S2A). Intriguingly, PIDDosome-deficient cells showed a polyploidization pattern similar to p53−/− hepatocytes (Figure 2C).

Albeit starting from a different baseline, the overall increase in ploidy was again significantly higher compared to that seen in WT controls (Figures 2A–2C). Seven days post-PH, PIDDosome-deficient, as well as p53−/− livers, reached an at least 2-fold higher increase in mean ploidy, compared with livers from WT mice (Figures 2B and 2C). Whereas the weighted mean DNA content per cell increased on average by 18% in the WT, the increase observed in PIDDosome- or p53-deficient livers ranged from 50% to 90% after 7 days of regeneration (Figure 2B). Histopathological analysis of liver sec-

tions confirmed differences in cell size and frequency of binu-

cleation (Figures 2F–2I). Moreover, the peak in ploidy was observed at 96 h in the absence of the PIDDosome, whereas the mean ploidy of WT hepatocytes began to decline already after 72 h, indicating altered proliferation dynamics (Figures 2A and 2C). Strikingly, Casp2−/− livers showed a prolonged proliferation phase, reflected by a higher mitotic index (Figures 2D, 2F, and S2B). Moreover, the significantly increased relative liver weight (LW/BW) 72 h post-resection clearly shows accel-

erated regeneration of Casp2−/− livers (Figures 2D–2F). Yet, 7 days post-resection, both WT and Casp2−/− animals have recovered their original liver mass. Similarly, albeit transiently increased ALT levels at 48 h in PIDDosome-deficient mice, liver integrity and function were similar between genotypes after 7 days, as indicated by comparable serum levels of liver en-

zymes, lipids, bilirubin, and urea (Figures 2D and S2C). These findings document that the PIDDosome limits the degree of polyploidization and the kinetics of liver regeneration.

Aneuploidy in the Liver Increases with Ploidy but Is Not Limited by Caspase-2

Caspase-2 was proposed to be required for the clearance of aneuploid tumor cells and low expression levels were shown to facilitate aneuploidy tolerance in colorectal cancer patients (Dawar et al., 2016; López-García et al., 2017). Consistent with massively increased polyploidization, Casp2−/− livers frequently showed multipolar mitoses and multinucleation in histological sections, suggesting less proficient chromosome segregation during regeneration that may drive aneuploidy (Figures 3A–3C and S2A).

To analyze chromosomal stability, we performed single-cell sequencing of WT and Casp2−/− hepatocytes. Cells were isolated either before or 7 days after PH when regeneration is completed. Based on their DNA content, hepatocyte nuclei were sorted, and 48 cells of each ploidy state and genotype were subjected to low-coverage whole genome sequencing, as described by Bakker et al. (2016). This analysis revealed that only a very low fraction of hepatocytes were indeed aneuploid, displaying either whole chromosome or structural alterations (Figures 3D–3F and S3A). The degree of aneuploidy clearly increased with the basal level of poly-

ploidy but was independent of the genotype analyzed (Figures 3D–3F and S3A). Forcing polyploid cells into proliferation during liver regeneration did not lead to a considerable increase in aneuploidy. However, we observed a higher degree of copy number variations in the octaploid fraction of regenerated Casp2−/− hepatocytes (Figure 3E). As this occurred in the absence of notable cell death (Figure S3D), we conclude that the increased level of aneuploidy seen is most likely a secondary consequence of multipolar mitoses, as about 1% of caspase-2 deficient hepatocytes harbor more than two nuclei at the time of analysis (Figure 3C). These data suggest that caspase-2 is not directly involved, arguing against a role in deleting aneuploid cells, at least in the healthy or regenerating liver. However, caspase-2 impacts aneuploidy by restricting the degree of basal ploidy levels in the liver.

Proliferating Adult Hepatocytes Engage the PIDDosome-p53-p21 Axis to Restrict Polyploidization

Given the noted downregulation of the PIDDosome after wean-

ing and the differences in polyploidy after PH, we analyzed mRNA and protein expression of all PIDDosome components during regeneration. We found strong induction of Casp2 and Pidd1 mRNA, as well as caspase-2 protein, during liver regeneration. Reminiscent of post-weaning development, Raidl mRNA and protein were unchanged. Casp2 and Pidd1 mRNA levels peaked at 48 h post-PH suggesting a link be-

tween expression levels and proliferation. At the same time p53 was stabilized in a PIDDosome-dependent manner (Figures 4A and 4B). Along with it, p21 expression was strongly induced in WT hepatocytes whereas p21 mRNA levels were significantly lower in PIDDosome- and p53-deficient cells (Figures 3A and 3C). Since the PIDDosome is activated by extra centrosomes, we reasoned that p21 would be preferentially induced in polyploid hepatocytes. Using IHC, we correlated p21 protein levels with cell size. Indeed, 72 h post-resection, p21 protein was predominantly induced in polyploid cells,
defined as binucleated cells and hepatocytes containing nuclei with twice the diameter of those of pericentral, presumably diploid, hepatocytes (Figures 4D and 4E). In contrast, p21 levels were significantly lower in Casp2−/−/C0 livers and showed no difference between ploidy states. Together, these data demonstrate that hepatocytes reactivate the PIDDosome to limit proliferation rates after cell cycle re-entry in a polyploid state (Figures 2D, 2E, and 4E).
Figure 3. Aneuploidy in the Liver Increases with Overall Ploidy but Is Not Limited by Caspase-2
(A) H&E stained liver sections at 72 and 96 h post-PH of WT and Casp2−/− mice. Dashed lines mark cells with multiple nuclei and green arrows indicate mitotic hepatocytes.
(B) Examples of aberrant mitoses and cells with >2 nuclei in Casp2−/− liver 96 h post-PH.
(C) Quantification of multinucleation (cells with >2 nuclei) during liver regeneration in WT and Casp2−/− mice. n = 3–8 (Table S7), scale bars represent 100 μm; mean ± SEM; ****p < 0.0001.
(D) Genome-wide heatmaps showing copy number variation (CNV) found in WT and Casp2−/− hepatocytes. 48 nuclei of n = 2–4 mice were sequenced per condition. Non-robust or erroneous libraries were excluded by two-step quality control.

(legend continued on next page)
Human Hepatocytes Engage the PIDDosome during Liver Regeneration

To explore conservation of mechanism, we first made use of the human hepatocellular carcinoma cell line, HepG2. In accordance with previous experiments in human A549 lung adenocarcinoma cells (Fava et al., 2017), perturbing cytokinesis using the AuroraB kinase inhibitor, ZM447439, resulted in PIDDosome-dependent and caspase-2-directed proteolysis of MDM2 and p53 stabilization (Figure S5A). Upon loss of either PIDDosome component, cleavage of MDM2 was abrogated and p53 levels were strongly reduced (Figure 5A). This confirms that the PIDDosome can control p53 in response to cytokinesis failure in human hepatocytes.

To provide first evidence that the PIDDosome may also be relevant for ploidy control in primary hepatocytes, we next tested whether its regulation can be observed during liver regeneration. We isolated RNA from patients undergoing liver surgery according to the ALPPS (associating liver partition and portal vein ligation for staged hepatopancreatoduodenectomy) procedure. Thereby, the regenerative capacity of the liver is exploited to allow resection of hepatic tumors or liver-metastases, which cannot be removed by standard staged resection (Schnitzbauer et al., 2012). During the first surgery, ligation of the portal vein and in situ splitting of one liver lobe induces enhanced proliferation in the other liver lobe. The split lobe is then removed in a second surgery 5–15 days later. Tissue biopsies of healthy liver, sampled from the regenerating lobe during the first and second surgery of five patients diagnosed with metastatic colorectal carcinoma undergoing the ALPPS procedure, were analyzed (clinical data shown in Table S1).

Recapitulating our results in mice and in line with previous observations, hepatocyte ploidy increased during regeneration (Figures 5B and 5C) (Schnitzbauer et al., 2012). We assessed mRNA levels of E2F1 and CCNA2 (Cyclin A2) and found that hepatocytes of four out of five patients actively proliferate, indicating ongoing liver regeneration. Strikingly, p21 mRNA levels were found generally increased in the regenerating livers, which coincided with an at least 2.5-fold induction of CASP2 mRNA, seen in four out of five patient samples (Figure 5D). Patient #2 who failed to induce CASP2 mRNA did also not show signs of proliferation, as reflected by reduced E2F1 and steady CCNA2 expression. Of note, this patient also presented with liver dysfunction after both surgeries (Figure 5D; Table S1). PIDD1 mRNA expression, was found to only mildly increase in 4/5 samples analyzed while RAIDD mRNA levels differed strongly between patients (Figure S4A), indicating the need for more detailed follow up studies on larger patient cohorts to time-resolve their regulation dynamics. However, considering the time between biopsy sampling in the different patients for a pseudo time-course analysis, CCNA2 and p21 induction followed a similar behavior, as observed during murine liver regeneration (Figure 5E). Taken all together, these data suggest that the PIDDosome contributes to p21 mRNA induction in the regenerating human liver to prevent excessive polyploidization during regeneration.

An E2F Regulatory Circuit Instructs PIDDosome Expression and Function in Hepatocytes

The above described data indicate that expression of CASP2 and PIDD1 in hepatocytes is coupled to proliferation during development and regeneration. To gain first information on the transcriptional control of the PIDDosome, we analyzed genes co-expressed with CASP2, PIDD1, and RAIDD that we retrieved from the STRING database (Szklarczyk et al., 2019). For CASP2 and PIDD1 the associated hallmark gene sets and GO terms mainly included pathways related to proliferation. Strikingly, the highest significance and overlap was found with genes of the hallmark pathways “G2/M checkpoint” and “E2F targets” (Figures 6A, S5A, and S5B). Next, we also analyzed the MSigDB transcription factor target data set, which includes information on putative transcription factor binding motifs. Genes co-expressed with CASP2 and PIDD1 were mostly E2F targets (Figure 6B). In contrast, no significant results were found for RAIDD. Of note, E2F transcription factor family members are crucial for hepatocyte polyploidization (Chen et al., 2012; Conner et al., 2003; Pandit et al., 2012) and showed an expression pattern similar to CASP2 and PIDD1 during liver development and regeneration (Figure 6C).

Intriguingly, sequence analysis of the murine and human CASP2, PIDD1, and RAIDD/CRADD promoter regions revealed that their 5'UTRs contain canonical E2F binding motifs (Figure 6D). Hence, we analyzed available ChIP-seq data sets for promoter occupancy with E2F1, E2F7, and E2F8. Both replicates of the ENCODE HeLaS3 cell samples showed strongly enriched E2F1 peaks near the transcription start sites (TSS) of CASP2 and PIDD1 (Figures 6D and S5C; Tables S2 and S3). E2F7 and E2F8 were also both significantly enriched at the CASP2 promoter (Figure 6D; Tables S4 and S5). No E2F7 or E2F8 peaks could be called for the PIDD1 proximal promoter, although visual inspection suggested some enrichment at the same genomic position near the PIDD1 TSS as the E2F1 peak (Figure 6D). In contrast, none of these transcription factors were found in the RAIDD promoter region. Analysis of data sets of an additional experiment, performed in primary mouse hepatocytes overexpressing human E2F1, confirmed these results showing a 3.71- and 23.38-fold enrichment in the TSS of Casp2 and Pidd1, respectively (GEO GSE74006) (Denechaud et al., 2016) (Figure 5C). To validate these results experimentally, we manipulated expression levels of the respective E2F family members and assessed the levels of CASP2, PIDD1, and RAIDD/CRADD expression. Doxycycline-induced overexpression of E2F7 or E2F8 in RPE1 cells significantly reduced CASP2 transcript levels. Again, no effect was observed on RAIDD mRNA but expression of PIDD1 was reduced upon E2F8 induction. Repression of CCNE1 by E2F7 or E2F8 served as an internal control (Figure 7A). Transcriptional repression by E2F7 or E2F8 also resulted in decreased caspase-2 protein levels while neither RAIDD nor PIDD1 showed a substantial reduction at the time of analysis.

Developmental Cell 52, 335–349, February 10, 2020 341

(E) Aneuploidy scores for each genotype, time point, and ploidy state show increasing CNV in octaploid samples. Robustly sequenced nuclei per condition: WT prePH (4c) = 34, WT prePH (8c) = 33, WT 7 days PH (4c) = 49, WT 7 days PH (8c) = 49, Casp2−/− prePH (4c) = 39, Casp2−/− prePH (8c) = 35, Casp2−/− 7 days PH (4c) = 75, and Casp2−/− 7 days PH (8c) = 75. Black dots mark samples shown in (D), data are represented as median.

(F) Single-cell plots from cells isolated after PH from WT and Casp2−/− livers with a basal ploidy of 8c showing a high degree of whole chromosome and structural CNV. All single-cell plots are deposited in Mendeley Data (https://data.mendeley.com/datasets/vfgvvhcvf5/1).
Figure 4. Adult Hepatocytes Induce and Activate the PIDDosome-p53-p21 Axis to Restrict Excessive Polyploidization during Regeneration

(A) Immunoblot analysis assessing CASP2, RAIDD, p53, and cyclin B1 expression in hepatocytes isolated from 14-week-old mice (0 h) before and 48 h and 7 days after PH.

(B) Transcript levels of Casp2, Raidd, and Pidd1 in isolated hepatocytes also shown in (A).

(legend continued on next page)
(Figures 7B and S6A). Transient overexpression of E2F1 in HepG2 cells resulted in marked increases in CASP2 and PIDD1 mRNA, but this finding was hard to reproduce by immunoblotting (Figure 7C, data not shown), potentially because E2F1 also increases levels of E2F7 and E2F8, which in turn repress caspase-2 in a negative feedback loop (Chen et al., 2009). Encouragingly, Casp2 transcript and protein levels were found to be higher in liver extracts from E2F1−/− E2F8−/− mice (Figures 7D and 7E). To confirm co-regulation at the time of weaning, we analyzed liver lysates from additional 3- or 4-week-old mice lacking E2F1, E2F7, and E2F8, or all three genes. Whereas no difference for caspase-2 protein expression could be observed in E2F1-deficient tissue samples, levels were strongly increased in E2F1−/− and E2F8−/− livers. Most importantly, the additional loss of E2F1 in triple knockout mice reduced caspase-2 expression to WT levels, confirming the proposed autoregulatory feedback loop (Figure 7F).

Taken together, these findings suggest that CASP2 and PIDD1 expression is controlled by the counteracting E2F family members E2F1, E2F7 and E2F8. RAIDD, however, is not regulated by E2F proteins.

DISCUSSION

Hepatocyte polyploidization is induced at the time of weaning where rapid liver growth meets drastic changes in metabolic load (Celton-Morizur et al., 2009; Pandit et al., 2013). Although the role of hepatocyte ploidy in normal physiology remains uncertain, as changes in either direction do not affect liver size or function, recent evidence suggests tumor suppressive effects. This has been ascribed to increased ploidy slowing down proliferative capacity of hepatocytes (Wilkinson et al., 2016) and generating a reservoir of tumor suppressors (Zhang et al., 2018a, 2018b).

Here, we show that the PIDDosome-p53-p21 axis is activated in hepatocytes where it controls the extent of polyploidization during juvenile development. Timewise, the PIDDosome is activated approximately after the first round of cytokinesis failure in hepatocytes, as indicated by the disappearance of the pro-form of caspase-2, a surrogate marker of its activation (Butt et al., 1998), on day 5 post-weaning (Figure 1). Although not formally demonstrated here, this occurs presumably in response to extra centrosomes (Faggioni et al., 2011). Remarkably, despite the fact that livers from Casp2−/− mice contained fewer cells that were on average bigger in size, the overall architecture of the liver parenchyma was unaffected by the noted ploidy increase (Figures 2F–2I). Moreover, serum levels of different enzymes and metabolites reflecting liver function and integrity were not altered significantly in steady-state conditions in young and aged mice lacking the PIDDosome (Figure S1B), again raising the question of the physiological relevance of liver cell ploidy.

As polyploid hepatocytes accumulate extra centrosomes, a hallmark of many cancers, tight cell cycle regulation after failed cytokinesis seems key to secure chromosomal stability in the liver. Proliferation in a polyploid state can increase CIN, either by merotelic kinetochore-microtubule attachments occurring frequently when centrosomes cluster, or multipolar mitoses (Holland and Cleveland, 2009). We analyzed copy number alterations in different polyploid states and found low aneuploidy rates in tetraploid hepatocytes, consistent with findings by Amon and colleagues (Knouse et al., 2014). However, the degree of aneuploidy clearly increased with polyploidy, as shown in octaploid hepatocytes (Figure 3). In hexa-decaploid (16c) hepatocytes we observed an even further increase in copy number alterations, but due to the small relative differences between copy number states, quantitative analysis of these data was of limited statistical robustness (Figures S3A and S3B). Our results clearly demonstrate that aneuploidy increases with the basal ploidy in the liver, yet this only poses a risk for transformation in the presence of an additional oncogenic driver (Zhang et al., 2018a). Although caspase-2 is dispensable for the clearance of aneuploid cells in the healthy liver, its loss indirectly leads to a relative increase in overall aneuploidy owed to higher basal levels of polyploidy. Interestingly, in line with the higher frequency of multipolar mitoses and multinucleated cells, the degree of copy number variations tended to be higher in caspase-2 deficient octaploid hepatocytes after regeneration (Figure 3). Together, this suggests that the PIDDosome limits the risk for hepatocyte transformation. This is consistent with a recent report showing that increased ploidy, here caused by conditional overexpression of Cyclin E1, is sufficient to increase CIN and to drive liver cancer in mice (Aziz et al., 2019).

Similar to development, liver regeneration in the absence of PIDDosome-dependent p53 activation clearly altered the polyploidization dynamics. Despite the different baseline ploidy, the relative increase in polyploidy during liver regeneration was drastically higher in PIDDosome-deficient mice (Figures 1 and 2). We speculate that in addition to impaired p21 induction, this is also a secondary consequence of the higher basal ploidy state in PIDDosome-deficient mice. Highly polyploid mitoses are error prone and lagging chromosomes and chromosomal bridges contribute to an increased rate of cytokinesis failure (Holland and Cleveland, 2009; Lens and Medema, 2019). Consistently, we frequently observed aberrant mitoses and multinucleation in H&E sections of Casp2−/− livers, which was barely seen in WT (Figures 3A–3C). While a recent report shows that WT hepatocytes effectively cluster centrosomes in situ (Knouse et al., 2018) the up to 2-fold higher ploidy in caspase-2 deficient cells and the corresponding number of extra centrosomes may prime for aberrant mitoses and subsequent defective cell divisions. Hence, the PIDDosome can prevent uncontrolled polyploidization either directly, on demand upon proliferation stress, or as a consequence of its ploidy-limiting action during development.

In the course of liver regeneration, p21 has been reported to be induced by several cues, including DNA damage caused by

(C) p21 mRNA levels analyzed in hepatocytes also displayed in (A) from indicated genotypes either before (0 h) or 48 h and 7 days after PH.
(D) Representative IHC images (20×) of WT and Casp2−/− livers stained for p21 at 48, 72, and 96 h post-PH.
(E) p21 expression was quantified as percentage of low ploid versus polyploid hepatocytes (n = 3). Polyploidy is defined as >2× diameter of pericentral hepatocyte nuclei and binucleated cells. n = 3–6 (Table S7); scale bars represent 100 μm, mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
proliferation in a polyploid state (Holland and Cleveland, 2009; Janssen et al., 2011; Karimian et al., 2016). Here, we demonstrate clearly that the at least 3-fold higher p21 levels, predominantly seen in polyploid WT hepatocytes, solely depend on PIDDosome-mediated p53 activation and are likely not a secondary consequence of DNA damage. This results in reduced proliferative capacity of polyploid hepatocytes, a phenomenon that has recently been reported by Wilkinson and colleagues (Wilkinson et al., 2018). We provide evidence that polyploid hepatocytes engage the PIDDosome during the regeneration process to reduce proliferation via p53-mediated p21 induction to avoid excessive polyploidization.

Figure 5. Human Hepatocytes Engage the PIDDosome during Liver Regeneration

(A) HepG2 cells were genome-edited using CRISPR/Cas9 with sgRNAs targeting either mouse CD8 (control) or the individual PIDDosome components. Bulk cultures were treated with ZM447439 or DMSO for 72 h and analyzed by immunoblotting.

(B) Representative images including zoom-ins of cryo-sections from patient #5 undergoing ALPPS, sampled during the first and second resection. The sections were stained for DNA (hovechst 33342) and β-catenin to visualize cell boundaries; scale bar represents 20 μm.

(C) Nuclear size was measured in tissue sections of patients #1 and #5 also shown in (B). Quantification shows increased nuclear size during or after regeneration at the second resection; data are represented as median of all cells measured per patient; ****p < 0.0001.

(D) Transcript levels of E2F1, CCNA2, CASP2, and p21 were assessed in matched RNA samples of ALPPS patients. Tissue biopsies were isolated during the first and second surgery.

(E) CCNA2 and p21 levels in patients shown in (D) are displayed based on the time between first and second resection (regeneration time, see Table S1). Due to liver dysfunction and unchanged CCNA2 levels, indicating no proliferative response during regeneration, patient #2 was excluded from this analysis.
Finally, we demonstrate that CASP2 and PIDD1 are dynamically regulated by E2F transcription factors, which directly link PIDDosome activity to hepatocyte proliferation (Figures 6 and 7). The atypical members of this transcription factor family, E2F7 and E2F8, were shown to repress transcription of various genes required for the execution of cytokinesis. The competing E2F1 counteracts the repressors and drives expression of the same target genes. Consistently, liver-specific loss of either E2F1 or E2F7/E2F8 results in hyper- and hypoploidization, respectively (Chen et al., 2012; Pandit et al., 2012). This autoregulatory loop implemented by E2F family members guarantees an ordered polyploidization process by controlling proliferation, on the one hand, and cytokinesis stringency as well as cell-cycle arrest proficiency, on the other.

Figure 6. PIDD1 and CASP2 are Co-regulated with E2F Target Genes
(A) STRING data sets were analyzed for genes co-expressed with CASP2, PIDD1, or RAIDD. Co-expressed genes are ordered according to the associated Hallmark pathway (MSigDB) and significance level indicating co-regulation of CASP2 and PIDD1 with E2F targets and other proliferation-related genes.
(B) Co-expressed genes shown in (A) were analyzed for associated transcription factors.
(C) Transcript levels of E2f1, E2f8, and all PIDDosome components in isolated hepatocytes before (20 days) and at indicated time points after weaning, as well as during regeneration. ΔCt values were normalized to the adult, 14-week-old mice (n = 3-7, Table S7).
(D) ChIP-seq analyses for E2F1, E2F7, and E2F8 performed on DNA from HeLa-S3 cells show significant enrichment in the promoter region of CASP2 and PIDD1 genes. Data are represented as mean ± SEM; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
CASP2 by E2F7 and E2F8 is necessary to allow the hepatocytes to reach a physiologically normal, polyploid state. Conversely, re-expression during tissue regeneration, controlled by E2F1, secures an upper limit of ploidy since presence of the PIDDosome in cells carrying extra centrosomes results in its immediate activation. Notably, while two components of the PIDDosome are controlled by E2Fs, the adapter protein RAIDD is regulated differently as the protein remains stable over time, suggesting additional biological roles.

Even though homeostatic proliferation is quite low, hepatocytes need to proliferate to compensate for loss of functional liver parenchyma under pathophysiological conditions, such as fatty liver diseases or viral hepatitis. Compensatory proliferation in these diseases was reported to be accompanied by an increase in polyploidy (Gentric et al., 2015; Toyoda et al., 2005). Interestingly, several reports also show an upregulation of caspase-2 expression levels in human patients as well as in mouse models for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) (Kim et al., 2018; Machado et al., 2015). Aside from its involvement in fat metabolism, these reports confirm that caspase-2 regulation is coupled to proliferation under stress conditions, which have the potential to increase liver ploidy.

Of note, we found that human HCC-derived HepG2 cells also engage the PIDDosome for p53 activation in response to cytokinesis failure. Most importantly, hepatocytes in the regenerating human liver from patients that underwent liver surgery according
to the ALPPS procedure (Schnitzbauer et al., 2012) show a pattern of PIDDosome expression and p21 induction similar to that observed in mice (Figure 5). This clearly suggests that the same signaling network is employed during human liver regeneration to control hepatocyte polyploidization. Together, these findings strongly suggest that murine and human hepatocytes engage the PIDDosome for ploidy control to avoid adverse effects of excessive polyploidization such as multipolar mitoses and potentially CIN. On the other hand, PIDDosome-mediated p21 induction leads to a delay in liver mass regeneration, which increases the risk of post-surgical complications and infection in humans (Van Den Broek et al., 2008; Rahbari et al., 2011). Of note, it has been shown before that depletion of p21 suffices to overcome delayed regeneration after extended hepatectomy in mice, a model of the “small-for-size syndrome” observed in humans (Lehmann et al., 2012). This finding is especially relevant for patients with a small liver remnant after resection, which might result in liver failure due to impaired or strongly delayed regeneration (small-for-size-syndrome) (Clavien et al., 2010). Hence, reducing p21 levels by inhibition of the PIDDosome could be exploited therapeutically to accelerate liver regeneration.

ACKNOWLEDGMENTS

We are grateful to I. Gaggl, K. Rossi, M. Fischer, N. Schöpf, and A. Beierfuß for excellent technical assistance or animal care. We also thank A. Strasser and T. Mak for sharing mouse models and reagents, as well as M. Bergmann, S. Geley, A. Curinha, and G.F. Vogel for fruitful discussions and support with microscopy. This work was supported by the FWF-funded Doctoral College “Molecular Cell Biology and Oncology” (W1101) to V.C.S. and F.W.F. Grant nos. P 28856 and PIR 3 and the ERC AdG POLICE (781711) to A.V. L.L.F. acknowledges support by the Giovanni Arnim-Harvard Foundation.

AUTHOR CONTRIBUTIONS

V.C.S. designed and conducted the experiments, wrote the manuscript, and analyzed the data. S.S. assisted with animal experiments. K.K., C.S., J.H., F.E., L.R.R., E.M., and E.A.V.M. performed the experiments. B.W. analyzed the ChIP-seq data. L.B. and A.d.B. performed histological analyses. M.T. enabled hepatectomy experiments. L.F. initiated research and analyzed data. T.G.S. performed bioinformatic analyses. P.S. and D.P. provided ALPPS patient biopsies. B.B., D.S., R.W., and F.F. conducted single-cell whole genome sequencing and analyzed the results. T.S. and H.S. analyzed serum parameters. A.V. designed the research, analyzed the data, wrote the manuscript, and conceived the study.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: May 16, 2019
Accepted: December 24, 2019
Published: January 23, 2020

REFERENCES


# STAR METHODS

## KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat monoclonal anti Casp2 (11B4)</td>
<td>Enzo Life Science</td>
<td>Cat# ALX-804-356; RRID:AB_2275199</td>
</tr>
<tr>
<td>Mouse monoclonal anti PIDD1 (Anto-1)</td>
<td>Enzo Life Science</td>
<td>Cat# ALX-804-837; RRID:AB_2297204</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-RAIDD</td>
<td>Proteintech</td>
<td>Cat# 10401-1-AP; RRID:AB_2085477</td>
</tr>
<tr>
<td>Rabbit polyclonal anti p21 (M-19)</td>
<td>Santa Cruz Technologies</td>
<td>Cat# sc-471; RRID:AB_2341188</td>
</tr>
<tr>
<td>Mouse monoclonal anti p53 (1C12)</td>
<td>Cell Signaling Technology</td>
<td>Cat# 2524; RRID:AB_331743</td>
</tr>
<tr>
<td>Mouse monoclonal anti E2F-1 (KH95)</td>
<td>Santa Cruz Technologies</td>
<td>Cat# sc-251; RRID:AB_627476</td>
</tr>
<tr>
<td>Mouse monoclonal anti-CyclinB1 (V152)</td>
<td>Abcam</td>
<td>Cat# ab72; RRID:AB_305751</td>
</tr>
<tr>
<td>Mouse monoclonal anti MDM2 (IF2)</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# 33-7100; RRID:AB_2533136</td>
</tr>
<tr>
<td>Mouse monoclonal anti Hsp90</td>
<td>Santa Cruz Technologies</td>
<td>Cat# sc-13119; RRID:AB_675659</td>
</tr>
<tr>
<td>Mouse monoclonal anti GAPDH (14C10)</td>
<td>Cell Signaling Technology</td>
<td>Cat# 2118; RRID:AB_561053</td>
</tr>
<tr>
<td>Mouse monoclonal anti cleaved caspase-3 (5A1E)</td>
<td>Cell Signaling Technology</td>
<td>Cat# 9661S; RRID:AB_2341188</td>
</tr>
<tr>
<td>HRP-mouse anti rat</td>
<td>Cell Signaling Technology</td>
<td>Cat# 7077; RRID:AB_10694715</td>
</tr>
<tr>
<td>HRP-rabbit anti mouse</td>
<td>Agilent</td>
<td>Cat# P0161; RRID:AB_2687969</td>
</tr>
<tr>
<td>HRP-goat anti rabbit</td>
<td>Agilent</td>
<td>Cat# P0448; RRID:AB_2617138</td>
</tr>
<tr>
<td>Biotin-goat anti rabbit</td>
<td>Vector laboratories</td>
<td>Cat# BA-1000; RRID:AB_2313606</td>
</tr>
<tr>
<td>Mouse monoclonal anti ßcatenin (14)</td>
<td>BD Bioscience</td>
<td>Cat# 610154; RRID:AB_397555</td>
</tr>
<tr>
<td>Alexa flour 546 goat anti mouse</td>
<td>Thermo Fisher</td>
<td>Cat# A-11030; RRID:AB_2534089</td>
</tr>
</tbody>
</table>

**Bacterial and Virus Strains**

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>DH5 alpha</td>
<td>Lab of Stephan Geley</td>
<td>N/A</td>
</tr>
<tr>
<td>XL1-Blue MR Supercompetent Cells</td>
<td>Agilent</td>
<td>2002229</td>
</tr>
</tbody>
</table>

**Biological Samples**

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human liver biopsies (ALPPS)</td>
<td>Patrick Starlinger, Medical University of Vienna, A</td>
<td>N/A</td>
</tr>
<tr>
<td>Liver tissue samples from FVB wt, FVB E2f1-/-, FVB E2f7-/-E2f8-/-, FVB E2f1-/-E2f7-/-E2f8-/- mice</td>
<td>Lab of Alain de Bruin, Utrecht University, NL</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Chemicals, Peptides, and Recombinant Proteins**

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoflurane (Forane®)</td>
<td>AbbVie</td>
<td>CAS# 26675-46-7</td>
</tr>
<tr>
<td>Buprenorphine (Temgesic)</td>
<td>Indivior UK Limited</td>
<td>CAS# 52485-79-7</td>
</tr>
<tr>
<td>Ketamine</td>
<td>AniMedica</td>
<td>CAS# 1867-66-9</td>
</tr>
<tr>
<td>Xylazine</td>
<td>AniMedica</td>
<td>CAS# 0007361-61-7</td>
</tr>
<tr>
<td>Piritramid (Dipidolor)</td>
<td>Piramal Critical Care</td>
<td>CAS# 302-41-0</td>
</tr>
<tr>
<td>Liberase TM</td>
<td>Sigma-Aldrich</td>
<td>#540119001</td>
</tr>
<tr>
<td>DMEM</td>
<td>Sigma-Aldrich</td>
<td>D5671</td>
</tr>
<tr>
<td>FBS (fetal bovine serum)</td>
<td>PAA laboratories</td>
<td>A15-151</td>
</tr>
<tr>
<td>L-glutamine</td>
<td>PAA laboratories</td>
<td>M11-00</td>
</tr>
<tr>
<td>Penicillin/Streptomycin</td>
<td>PAA laboratories</td>
<td>P11-010</td>
</tr>
<tr>
<td>TissueTek O.C.T.</td>
<td>Sakura Europe</td>
<td>#4583</td>
</tr>
<tr>
<td>Hoechst 33342</td>
<td>Sigma-Aldrich</td>
<td>CAS#: 23491-52-3</td>
</tr>
<tr>
<td>ZM447439</td>
<td>Selleck Chemicals</td>
<td>S1103</td>
</tr>
<tr>
<td>PEI (Polyethyleneimine)</td>
<td>Sigma-Aldrich</td>
<td>CAS#: 9002-98-6</td>
</tr>
<tr>
<td>Puromycin</td>
<td>Sigma-Aldrich</td>
<td>P8833</td>
</tr>
<tr>
<td>Blasticidin</td>
<td>Sigma-Aldrich</td>
<td>P15205</td>
</tr>
<tr>
<td>Phusion polymerase</td>
<td>New England Biolabs</td>
<td>M0530</td>
</tr>
<tr>
<td>BamHI</td>
<td>New England Biolabs</td>
<td>R3136S</td>
</tr>
</tbody>
</table>

(Continued on next page)
## REAGENT or RESOURCE SOURCE IDENTIFIER

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>XbaI</td>
<td>New England Biolabs</td>
<td>R0145S</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>Sigma-Aldrich</td>
<td>CAS#: 24390-14-5</td>
</tr>
<tr>
<td>Oligofectamine</td>
<td>Life Technologies</td>
<td>12252-011</td>
</tr>
<tr>
<td>OptiMem</td>
<td>Life Technologies</td>
<td>31985-054</td>
</tr>
<tr>
<td>MetaFectene</td>
<td>Biontex</td>
<td>T020-0.2</td>
</tr>
<tr>
<td>EDTA free protease inhibitor cocktail</td>
<td>Roche</td>
<td>11836170001</td>
</tr>
<tr>
<td>DNasel</td>
<td>Sigma-Aldrich</td>
<td>4716728001</td>
</tr>
<tr>
<td>Bradford reagent</td>
<td>Bio-rad</td>
<td>500-0006</td>
</tr>
<tr>
<td>TRIzol reagent</td>
<td>Ambion, LifeTechnologies</td>
<td>15596018</td>
</tr>
<tr>
<td>AceQ qPCR SYBR Green Master Mix</td>
<td>Vazyme</td>
<td>Q131-02</td>
</tr>
<tr>
<td>AceQ qPCR Probe Master Mix</td>
<td>Vazyme</td>
<td>Q112-02</td>
</tr>
</tbody>
</table>

### Critical Commercial Assays

<table>
<thead>
<tr>
<th>Commercial Assay</th>
<th>Source</th>
<th>Catalog Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vectastain ABC Kit</td>
<td>Vector Laboratories</td>
<td>PK-6100</td>
</tr>
<tr>
<td>ImmPACT DAB</td>
<td>Vector Laboratories</td>
<td>SK-4105</td>
</tr>
<tr>
<td>Gibson Assembly® Cloning Kit</td>
<td>New England Biolabs</td>
<td>E5510S</td>
</tr>
<tr>
<td>Plasmid Midi Kit</td>
<td>Qiagen</td>
<td>12143</td>
</tr>
<tr>
<td>iScript cDNA synthesis kit</td>
<td>Bio-rad</td>
<td>170-8891</td>
</tr>
</tbody>
</table>

### Deposited Data

<table>
<thead>
<tr>
<th>Data Type</th>
<th>Data Description</th>
<th>Paper</th>
<th>URL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single cell whole genome sequencing data</td>
<td>This paper</td>
<td>PRJEB3254</td>
<td><a href="https://www.ebi.ac.uk/ena">https://www.ebi.ac.uk/ena</a></td>
</tr>
<tr>
<td>Single cell whole genome sequencing profile plots</td>
<td>This paper; Mendeley data</td>
<td><a href="https://doi.org/10.17632/vfpgvhcvh5.1">https://doi.org/10.17632/vfpgvhcvh5.1</a></td>
<td></td>
</tr>
<tr>
<td>ChIP-seq E2F1, HeLaS3</td>
<td>The ENCODE project</td>
<td>ENCSR000EUV</td>
<td><a href="https://www.encodeproject.org/">https://www.encodeproject.org/</a></td>
</tr>
<tr>
<td>ChIP-seq E2F7 and E2F8, HeLaS3</td>
<td>Pandit et al., 2012</td>
<td>GSE32673</td>
<td><a href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</a></td>
</tr>
<tr>
<td>ChIP-seq E2F1 primary mouse hepatocytes</td>
<td>Denechaud et al., 2016</td>
<td>GSE74006</td>
<td><a href="https://www.ncbi.nlm.nih.gov/geo/">https://www.ncbi.nlm.nih.gov/geo/</a></td>
</tr>
</tbody>
</table>

### Experimental Models: Cell Lines

<table>
<thead>
<tr>
<th>Model</th>
<th>Source</th>
<th>RRID</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEK293T (female)</td>
<td>Lab of Alain de Bruin</td>
<td>CVCL_0063</td>
</tr>
<tr>
<td>HepG2 (male)</td>
<td>Lab of Lukas Huber</td>
<td>CVCL_0027</td>
</tr>
<tr>
<td>RPE-hTert (female)</td>
<td>Lab of Alain de Bruin</td>
<td>CVCL_4388</td>
</tr>
</tbody>
</table>

### Experimental Models: Organisms/Strains

<table>
<thead>
<tr>
<th>Organism/Strain</th>
<th>Reference</th>
<th>RRID</th>
</tr>
</thead>
<tbody>
<tr>
<td>C57BL/6N Casp2−/−</td>
<td>O'Reilly et al., 2002</td>
<td>N/A</td>
</tr>
<tr>
<td>C57BL/6N Pidd1−/−</td>
<td>Manzl et al., 2009</td>
<td>N/A</td>
</tr>
<tr>
<td>C57BL/6N Radd−/−</td>
<td>Berube et al., 2005</td>
<td>N/A</td>
</tr>
<tr>
<td>C57BL/6N p53−/−</td>
<td>Lowe et al., 1993</td>
<td>N/A</td>
</tr>
<tr>
<td>C57BL/6N p21−/−</td>
<td>Brugarolas et al., 1995</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Oligonucleotides

<table>
<thead>
<tr>
<th>Oligonucleotide</th>
<th>Origin</th>
<th>Catalog Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>mCasp2 fw: TCTCACATGGTGTGGAAGGT</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>mCasp2 fw: AGGGGATTGTGTGTGGTTCT</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>m p21 fw: AATTGGAGTCAGGCGCAGAT</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>m p21 rev: CATGAGCGCATCGCAATCAC</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>PIDD1 predesigned qPCR probe assay</td>
<td>Integrated DNA Technologies</td>
<td>Hs.PT.58.3199598.gs</td>
</tr>
<tr>
<td>GAPDH predesigned qPCR probe assay</td>
<td>Integrated DNA Technologies</td>
<td>Hs.PT.39a.22214836</td>
</tr>
</tbody>
</table>

Additional oligonucleotides are reported in Table S2.

### Recombinant DNA

<table>
<thead>
<tr>
<th>Recombinant DNA</th>
<th>Source</th>
<th>Catalog Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>LentiCRISPRv2</td>
<td>Feng Zhang lab</td>
<td>Addgene Plasmid #52961</td>
</tr>
<tr>
<td>pMDLg pRRE</td>
<td>Didier Trono</td>
<td>Addgene plasmid #12251</td>
</tr>
</tbody>
</table>

(Continued on next page)
Further information and requests for reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Andreas Villunger (andreas.villunger@i-med.ac.at).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Human Patient Biopsies

Biopsy sampling was approved by the Institutional Ethics Committee at the Medical University of Vienna (#2032/2013) and all patients gave written informed consent. All patients underwent ALPPS procedure (associating liver partition and portal vein ligation for staged hepatectomy). Briefly, ligation of the portal venous branch for the right liver lobe combined with parenchymal transection in a first step lead to augmented liver regeneration. In a second step, approximately 5–15 days after the first step, the previously ligated liver lobe was resected (Schnitzbauer et al., 2012). Biopsies were sampled from the regenerating lobe at the beginning of each the first and second surgery. Five patients diagnosed with metastatic colorectal carcinoma were analyzed for mRNA levels. Cryo-sections derived from patients #1 and #5 were used for ploidy analysis. Details and clinical characteristics of these patients are provided in Table S1.
Animals

All animal experiments were approved by the Austrian Bundesministerium für Bildung, Wissenschaft und Forschung (Tierversuchsgesetz, 2012, BGBl I Nr. 114/2012, GZ 66.011/0093/WF/V/3b/2016). Generation and genotyping of Casp2−/−, Pidd1−/−, Raidd−/−, p53−/− and p21−/− mice were described before (Berube et al., 2005; Brugarolas et al., 1995; Lowe et al., 1993; Manzl et al., 2009; O’Reilly et al., 2002). The mice used were backcrossed and maintained on a C57BL/6N background for at least 12 generations and housed at the Medical University of Innsbruck. Only male mice were used for partial hepatectomy. Mice used for ploidy analysis before and after weaning as well as aged animals were sex balanced and analyzed at indicated time points. E2F1−/−, E2F7−/−E2F8−/−, E2F1−/−E2F7−/−E2F8−/− and the corresponding wt mice were kept on an FVB background as described before (Pandit et al., 2012). Liver tissue samples from these mice were collected in Alain de Bruin’s lab at Utrecht University, approved by the Utrecht University Animal Ethics Committee and in accordance with institutional and national guidelines. For details on age of the mice used refer to the respective figure legends or Table S7.

Cell Culture

HEK293T (RRID: CVCL_0063; female), HepG2 (RRID: CVCL_0027; male) and hTert-RPE-1 (RRID: CVCL_4388; female) cell lines were cultured at 37 °C with 5% CO2 in DMEM (Sigma-Aldrich, D5671) supplemented with 10% fetal bovine serum (FBS, PAA Laboratories, A15-151), 1% L-glutamine (PAA Laboratories, M11-004), 100 U/ml penicillin and 100 μg/ml streptomycin (PAA Laboratories, P11-010). Cytokinesis failure was induced by treatment with 1 μM ZM447439 (Selleck Chemicals, S1103) 24 h after seeding. Cells were harvested by trypsinization. All cell culture experiments were performed in three independent biological replicates.

METHOD DETAILS

Partial Hepatectomy

68% partial hepatectomy was performed according to Lehmann et al. (Lehmann et al., 2012). Mice were weighted and anesthetized by isoflurane inhalation (2-4%). For analgesia, buprenorphine (0.1 mg/kg BW) was injected s.c. 30 min before surgery. The mouse was incised at the linea alba. Following liver ligament removal, cholecystectomy was performed (Prolene, 9’0; Ethicon, Neuchatel, Switzerland). Subsequently, the lateral left, middle left and middle right lobe was individually ligated (silk, 6/0) and resected. During the procedure, anesthesia was monitored by reflexes, respiratory rate, and depth as well as color of mucous membranes and inner organs. Mice were allowed to recover on a heating pad and caged individually. After surgery, drinking water was supplemented with piritramid (0.06 mg/ml) and buprenorphine was injected s.c. up to 72h.

Hepatocyte Isolation

Primary mouse hepatocytes were isolated using a two-step collagenase perfusion adapted from (Grompe et al., 1992). In brief, mice were anesthetized (Ketamine/Xylasole i.p.), the vena cava inferior was canulated, clamped below the heart and the portal vein was incised. The liver was perfused with 70 ml (37 °C) perfusion buffer (0.14 M NaCl, 6.7 mM KCl, 10 mM Hepes, 0.1 mM EGTA, pH=7.4) at 7 ml/min and 40 ml collagenase buffer (66.7 mM NaCl, 6.7 mM KCl, 4.7 mM CaCl2·2H2O, 10 mM Hepes, pH=7.45) containing 25 μg/ml Liberase TM (Roche), 37 °C at 2.5 ml/min. The liver was gently disrupted in ice cold DMEM (Sigma-Aldrich, D5671) supplemented with 10 % FCS and 2 mM L-glutamine and the cell suspension was passed through a 100-μm cell strainer. Hepatocytes were separated from non-viable and non-parenchymal cells by three subsequent low speed centrifugations (30 g, 3 min) in the above described medium. Purity and yield of the isolation were assessed by light microscopy. Subsequently, cells were fixed in 70 % ethanol prior to ploidy measurement.

Immunohistochemistry

For immunostaining, tissue sections were deparaffinized and rehydrated in xylol and ethanol. Antigen retrieval was performed using 10-mM citrate buffer (pH 6.0). Following a blocking step in peroxidase solution (1% H2O2/TBS), sections were stained consecutively with primary and secondary antibody diluted in 5% goat serum/TBS. VECTASTAIN ABC Kit (Vector Laboratories, Cat# PK-6100) and ImmPACT DAB (Vector Laboratories, Cat# SK-4105) were used for amplification and development, respectively. After counterstaining with hematoxylin and dehydration, sections were mounted and images acquired on an Olympus BX45 microscope using cell^B software (version 2.7, Olympus Soft Imaging Solutions). All images were blinded before analysis.

Histopathological Examination

Histological analyses were performed by a board-certified veterinary pathologist. H&E stained 4-μm sections of paraffin-embedded liver were examined. Polyploidy was histologically defined as ≥2 times the nuclear diameter of pericentral hepatocytes as well as by counting binucleated cells. Mitotic index was determined by count of mitoses in 10 randomly selected fields (40x). The number of cells positive for active caspase-3 or p21-positive hepatocytes was assessed manually in 5 randomly chosen fields at 20× magnification. The total number of cells and positively stained cells, total number and p21-positive binucleated or cells with larger nuclei were measured using manually drawn masks (ImageJ, Schneider et al., 2012) and counted. Binucleated cells and hepatocytes with nuclei of at least twice the diameter as small, pericentral hepatocyte nuclei were considered as polyploid (Figure 2). Hepatocytes below this threshold were classified as low ploid. Images were acquired on an Olympus BX45 microscope using cell^B software (version 2.7, Olympus Soft Imaging Solutions). All images were blinded before analysis.
Immunofluorescence
Cryo-sections of TissueTek O.C.T. (Sakura Europe) embedded human liver biopsies were fixed in 4 % paraformaldehyde/PBS, stained for β-catenin (Alexa Fluor 546) and DNA (hoechst 33342) and mounted in Mowiol. Images were acquired on a Zeiss Axiovert 200M microscope with an oil immersion objective (PL APO 63 × 1.4 oil, Zeiss). The acquisition software VisiView 4.1.0.3 (Visitron Systems) was also used to generate maximum intensity projections of Z-stacks. Contrast and brightness of the images were adjusted with ImageJ (Schneider et al., 2012). The same software was used to determine nuclear size by manually drawn masks in a blinded fashion.

Single-Cell Whole Genome Sequencing
Snap-frozen liver tissue or suspension of isolated hepatocytes were used to isolate nuclei for sorting and sequencing as described by van den Bos et al. (2019). Hepatocyte suspensions were stored in FBS with 10% DMSO at -80 °C until further processing. Cells were thawed and immediately treated with nuclei staining buffer for cell lysis (100 mM Tris-HCl pH7.4, 154 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.2% bovine serum albumin, 0.1% NP40 in UltraPure water, 10 μg/ml hoechst 33358 and 10 μg/ml propidium iodide). Alternatively, snap frozen liver tissues were cut with a scalpel into small tissue pieces and incubated in nuclei isolation buffer (10 mM Tris-HCl pH8.0, 320 mM sucrose, 5 mM CaCl2, 3 mM Mg(AC)2, 0.1 mM EDTA, 1 mM DTT, 0.1% Triton X-100). Nuclei were subsequently gently pushed out of the tissue pieces through a 70 μm filter using a syringe plunger. After centrifugation, nuclei were re-suspended into PBS containing 2% bovine serum albumin and 10 μg/ml hoechst 33358 and 10 μg/ml propidium iodide. Sorting of single nuclei and library preparation were conducted as described previously (Bakker et al., 2016; van den Bos et al., 2019). Sequencing was performed using a NextSeq 500 (Illumina).

Single-Cell Sequencing Data Analysis
Single-cell whole genome sequencing and data were aligned to the murine reference genome (GRCm38) using Bowtie2 (v2.2.4) (Langmead and Salzberg, 2012; Li et al., 2009). For data analysis the developer version of AneuFinder 1.10.1 was used (Bakker et al., 2016). Following GC-correction, blacklisting of artifact-prone regions (extreme low or high coverage in control samples) and mappability checks, libraries were analyzed using the edivisive copy number calling algorithm using the following settings: fixed ground ploidy adjusted for ploidy state of the respective sample, variable bins (average size of 2Mb), 500kb step size, significance level of 0.05 and R equal to 20 (default). Breakpoints that were located within 5 Mb from each other (across libraries) were grouped. To exclude low quality libraries an additional data curation step was introduced based on total read counts and spikiness of the data, which reflect data variance. Low quality libraries are expected to have a relatively high number of segments and therefore also a high value for spikiness (one of the quality features of AneuFinder). Libraries above a spikiness of >0.11 or total read counts <0.25 Mb were excluded (Figure S3B).

The degree of aneuploidy for each library was calculated as the weighted average of the absolute difference between the observed and expected copy number of each bin. The expected copy number is equal to the copy number of the euploid genome. The aneuploidy score of the sample is the average of all the libraries of the same sample.

Serum Parameters
Serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, urea, cholesterol and triglycerides were measured enzymatically (Roche Diagnostics, Mannheim, Germany) on a cobas analyzer from Roche.

Cell Lysis and Immunoblotting
All samples were lysed in lysis buffer containing 50 mM Tris pH 8.0, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 1 tablet protease inhibitors (EDTA free, Roche) per 10 ml and 30 μg/ml DNaseI (Sigma-Aldrich). Protein concentration was determined using Bradford reagent (Bio-Rad, 500-0006). 50–100 μg of total protein was used for western blotting (AmershamTM HybondTM - ECL nitrocellulose membranes, GE Healthcare) using a wet-transfer system (BioRad). Immunoblots in Figure 7B were quantified using ImageJ.

RNA Isolation and qRT-PCR
Total RNA extraction was performed using Trizol reagent (Ambion, LifeTechnologies, 15596018) according to the manufacturer. 500 ng total RNA was used for generation of cDNA (iScript cDNA synthesis kit, BioRad, 170–8891). Quantitative real-time PCR was performed using either Vazyme, AceQ qPCR SYBR Green Master Mix (Q131-02) or Vazyme, AceQ qPCR Probe Master Mix (Q112-02) on a StepOne Plus real time PCR system (Applied Biosystems). Human PIDD1 was determined using a predesigned probe assay (PIDD1: Hs.PT.58.319958.gs; GAPDH Hs.PT.39a.22214836; Integrated DNA Technologies). Relative expression was calculated relative to a reference gene using the ΔΔCt method. GAPDH and HPRT served as reference genes for mouse and human samples, respectively.

Ploidy Measurement
Cell suspensions were fixed with 70 % ethanol in PBS at -20 °C for at least 30 min. Fixed cells were washed twice with PBS, filtered over a 100-μm cell strainer and stained with 40 μg/ml propidium iodide for 15 min or longer at 37 °C in the presence RNase A. The DNA content was measured on a flow cytometer (LSR-Fortessa, BD Biosystems) and data were analyzed quantitatively, excluding doublets, using FlowJo (FlowJo X, LLC).
Generation of Cell Lines
The CRISPR/Cas9 mediated knock out of CASP2, PIDD1 and RAIDD was performed using LentiCRISPRv2 backbone for vector production (gift from Feng Zhang; Addgene plasmid number 52961) (Sanjana et al., 2014). The small guide RNAs targeting the genes of interest were designed using CRISPR Design (http://crispr.mit.edu) and described before (Fava et al., 2017). Cloning was done as described in the protocol from Feng Zhang available at http://www.addgene.org. For transformation DH5αlpha bacteria were used. Lentiviral supernatants were produced in 293T packaging cells. After sequence-verification, cells were transfected with the plasmids generated before, together with the packaging plasmids pCMV-VSV-G and psPAX2 using 1 mg/ml polyethylenimine (PEI) at a ratio 1:2 DNA:PEI. The human hepatoma cells (HepG2) were incubated with the lentiviral supernatants and selected with 1 μg/ml puromycin for one week. Polyclonal (bulk) lines were characterized for depletion of target genes by immunoblotting and directly used in the experiments.

Mouse E2F7-EGFP and E2F8-EGFP and EGFP cDNA was amplified (Phusion polymerase; New England Biolabs) and cloned into the pLenti CMV/TO plasmid using the Gibson Assembly® Cloning Kit (New England Biolabs E5510S) according to the manufacturer’s instructions. For plasmid amplification, XL1-Blue MR Supercompetent Cells (Agilent) were transformed. Subsequently, plasmids were purified (Qiagen), control-digested (BamHI and XbaI) and the correct sequence was verified by sequencing (Macrogen). Generation of inducible cell lines was performed by introducing consecutively the pLenti CMV TetR and the respective E2F-containing plasmids into retinal pigment epithelium cells (RPE-hTert) cells using a third generation lentiviral packaging system. pLenti CMV TetR Blasts (716–1) and pLenti CMV/TO Puro DEST (670–1) were a gift from Eric Campeau & Paul Kaufman to Alain de Bruin’s lab (Addgene plasmids #17492; http://n2t.net/addgene:17492; RRID:Addgene_17492; and # 17293; http://n2t.net/addgene:17293; RRID:Addgene_17293). HEK293T were transfected with 10μg packaging plasmids at 70% confluency. pMDLg pRRE, pCMV-VSV-G, pRSV Rev, were mixed in a ratio 1:1:1 and transfected together with the pLenti constructs using polyethylenimine (PEI). Virus containing supernatant was used for infection of preseeded RPE-hTert cells with addition of 4 μg/ml polybrene. The medium was replaced by fresh DMEM containing 1% Pen-Strep and 10% Tet System Approved FBS after 16h. 20 μg/mL Blasticidin and 20 μg/mL Puromycin were used to select for cells which stably integrated the constructs. Monoclonal colonies were expanded and analyzed for high expression of the Tet-Repressor. Finally, the single-cell derived colonies with highest Tet-Repressor expression were infected with E2F7/8-EGFP. To ensure high Tet-Repressor expression (RPE-TetR), single-cell derived colonies were picked and analyzed by qPCR and screened for Tet-Repressor expression before proceeding to infection with E2F7/8-EGFP and EGFP constructs. To induce overexpression, cells were treated with 0.2μg/mL doxycycline (Sigma Aldrich) for 24h.

Plasmid Transfection
3 x10⁶ HepG2 cells per 6 cm dish were transfected with 6 μg plasmid DNA (pCDNA3.1-HA-E2F1 or pCDNA3.1-HA) using Metafectene (Biontex) following the manufacturer’s instructions 2.5 h after seeding. Cells were harvested and processed 72 h later.

ChIP-Seq Data Analysis
ChIP-sequencing peaks were called using MACS version 1.4.2 (Zhang et al., 2008) with a p value cutoff of 1E-5. Fold enrichments were calculated over their respective input controls. For E2F1, we used data generated in HeLa-S3 (ENCsR00017V) from the ENCODE project. Data for primary mouse hepatocytes transfected with human HA-E2F1 were retrieved from the NCBI’s Gene Expression Omnibus (GEO) database under the accession numbers GSE74006. For E2F7 and -8 in HeLa-S3, we used the dataset previously published by Alain de Bruin’s lab (GSE32673). The peaks within 1 kb upstream or downstream of transcription start sites were annotated to the human genome (HG19) using the R package ChIPpeakAnno (Zhu et al., 2010). Figures were created using the Bioconductor packages “GenomicRanges”, “IRanges”, “rttracklayer”, “bioArT”, and “chipseq” (Durinck et al., 2009; Lawrence et al., 2009, 2013; Sarkar et al., 2018)

STRING Data Analysis
Genes co-expressed with CASP2, RAIDD and PIDD1 were downloaded from the STRING database (https://string-db.org/) and filtered for a confidence score of co-expression greater than 0.05 (Szklarczyk et al., 2019). Most relevant terms related to the resulting gene lists were identified with the “enricher” function of clusterProfiler in R (Yu et al., 2012). Gene signatures for Hallmark gene sets, biological process GO terms and transcription factor targets were downloaded from the MSigDB database (http://software.broad institute.org/gsea/msigdb) using the msigdbR package (Subramanian et al., 2005). Top gene signatures were visualized using built-in functions of clusterProfiler (Wickham, 2009).

QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics and Data Analysis
The weighted mean ploidy was calculated as \( \bar{p} = \frac{\sum_{i=1}^{n} w_i x_i}{\sum_{i=1}^{n} w_i} \), with \( w \) = fraction of cells and \( x \) = ploidy state. The relative fold change in weighted mean ploidy was calculated as percentage after 7 days of regeneration based on the weighted mean ploidy before partial hepatectomy. Given a basal weighted mean ploidy of 8 before and a weighted mean ploidy of 12 after regeneration, the relative fold increase is 1.5 or 50 percentage points, respectively (Figure 2B). Depending on the type of data either Student’s t-test, one-way or two-way ANOVA with Sidak’s or Tukey’s multiple comparisons test was used to determine statistical significance. Correlation was
assessed by calculation of Spearman’s correlation coefficient (Figure 1F). For comparison of proliferation curves (Figure 2E), nonlinear regression with least-squares-fit was used and curves were compared by the extra sum-of-squared F test. For statistical parameters and significance please refer to the respective figure legends. If not specified otherwise in the figure legend, n represents the number of animals used. The exact number of mice used in the different experiments is shown in Table S7. Generation of graphs and data analysis was performed using Prism 7.00, GraphPad Software.

**DATA AND CODE AVAILABILITY**

The single-cell whole genome sequencing datasets generated in this study are available at ENA, accession number: PRJEB3254 (https://www.ebi.ac.uk/ena). The corresponding original single cell profile plots for these datasets are available on Mendeley Data (https://data.mendeley.com/datasets/vfpgvhcvh5/1; https://doi.org/10.17632/vfpgvhcvh5.1). ChiP-seq data were generated before and are accessible on the ENCODE project and the GEO database (ENCSR000EVJ; https://www.encodeproject.org/; GSE32673; GSE74006; (https://www.ncbi.nlm.nih.gov/geo/) (Denechaud et al., 2016; Pandit et al., 2012).